Market Cap $38 M--Cash $21 M -- 1 Drug launched for the treatment of Gaucher disease partnered with Pfizer -- Next Drug a potential Blockbuster for the treatment of Fabry disease close to BLA filing expected in April with potential FDA approval 6 months later .Brutally undervalued low float stock with MASSIVE upside potential could hit $15-20 next year .STRONG BUY Protalix BioTherapeutics (PLX) Market Cap $38 M Cash $21 M Price $2.60 Shares Out 14.8 M Company Highlights Big Dealwith Chiesi Potential to be gold standard therapy ( $1+ BILLION peak Sales) Pipeline
Presentation https://protalixbiotherapeutics.gcs-web.com/static-files/a455e93c-dc37-4422-a3be-8c869df48e21 Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States https://finance.yahoo.com/news/protalix-biotherapeutics-chiesi-farmaceutici-announce-115000421.html No additional clinical trials are necessary for BLA submission, expected by April of 2020 PRX-102 in Development for Fabry has Potential to be a Gold Standard Therapy, Once Fully Approved
